<DOC>
	<DOCNO>NCT02473640</DOCNO>
	<brief_summary>A Phase 1b/2a , Multi-Center , Open-Label , 2-Period , Fixed-Sequence Study Evaluating Effect Esomeprazole SYN-004 Degradation Ceftriaxone In Healthy Adult Subjects Functioning Ileostomy</brief_summary>
	<brief_title>A Study Evaluating Effect Esomeprazole SYN-004 Degradation Ceftriaxone In Adults With Ileostomy</brief_title>
	<detailed_description>This Phase 1b/2a , randomize , multi-center , open-label study . Twenty otherwise healthy subject function ileostomy age 18 70 year , inclusive , enrol . The entire duration study may 63 day ( Screening end-of-study [ EOS ] visit ) .</detailed_description>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>The subject function ileostomy place ≥ 3 month . The subject male female age 18 70 year , inclusive . Other function ileostomy , subject free clinically significant illnesses disease . Subjects active hepatic , small intestine , biliary tract disease . Subjects active ulcerative colitis , Crohn 's disease , inflammatory bowel disease . Subjects known malignancy require treatment &lt; 6 month prior study screen . Subjects , opinion investigator , significant concurrent medical illness . Subjects currently take concomitant medication may interfere study evaluation . Subjects received investigational drug within 30 day within time period consistent washout period 5 halflives , whichever longer , first dose ceftriaxone . Subjects know history allergy cephalosporin , penicillin βlactam antibiotic . Subjects know active malabsorption syndrome ( ) , judgment investigator , could compromise objective study . Subjects used oral , intramuscular , IV antimicrobial medication last 3 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>